nVerses Capital’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-2,753
Closed -$205K – 36
2026
Q2
$205K Buy
+2,753
New +$193K 0.32% 186

Other funds holding BBIO

nVerses Capital's BBIO Position: Q3 2026 in Review

nVerses Capital sold out of BridgeBio Pharma (BBIO) in Q3 2026, closing a stake of 2,753 shares — an estimated $205K sold.

nVerses Capital first reported a position in BBIO in Q2 2026 and held it in 1 quarter. The position peaked at $205K in Q2 2026. 469 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • nVerses Capital reported no remaining BridgeBio Pharma position as of Q3 2026 after selling out during the quarter.
  • nVerses Capital sold 2,753 BridgeBio Pharma shares in Q3 2026, an estimated $205K.
  • nVerses Capital first reported a position in BridgeBio Pharma in Q2 2026 and held it in 1 quarter.
  • nVerses Capital's BridgeBio Pharma position peaked at $205K in Q2 2026.
  • 469 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on nVerses Capital's 13F filing for Q3 2026.